EGRX Eagle Pharmaceuticals Inc.

56.89
-0.87  -2%
Previous Close 57.76
Open 57.75
Price To book 5.13
Market Cap 847661000
Shares 14,900,000
Volume 267,280
Short Ratio 8.20
Av. Daily Volume 426,629

SEC filingsSee all SEC filings

  1. 8-K - Current report 171093264
  2. 8-K - Current report 171082237
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171049994
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018492
  5. 8-K - Current report 171016396

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 30, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
  2. ETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017
  3. Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : September 19, 2017
  4. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017
  5. Eagle Pharmaceuticals, Inc. to Present at September Investor Conferences
  6. Eagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
  7. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  8. Eagle Pharmaceuticals, Inc.: Sudden move in price, will it continue?
  9. Edited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT
  10. Eagle Pharmaceuticals posts 2Q profit
  11. Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results
  12. ETFs with exposure to Eagle Pharmaceuticals, Inc. : August 4, 2017
  13. Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2017 Financial Results on August 9, 2017
  14. Mizuho Top Analyst Buzzes Mayday as Eagle Pharmaceuticals Inc (EGRX) Valuation Likely to Collapse
  15. FDA rejects Eagle Pharmaceuticals' heat stroke treatment
  16. UPDATE: Eagle Pharma stock plummets 21% on news that heat stroke drug failed to get FDA approval
  17. Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application
  18. Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke
  19. ETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017